Clinical Trial

Circulating Biomarker Signatures for the Detection of Gastric Preneoplasia and Cancer

Study acronym: PREGASIGN#1
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 16, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this study is to characterize and validate a signature of circulating biomarkers in plasma, associated with the presence of gastric preneoplasia in patients with preexisting gastric lesion compared with a control group. For this purpose: * Patients with pre-existing gastric lesions will be invited to participate to this study. If they are willing to participate an additional blood sample (9 mL) will be collected at the time of the blood collection performed during their routine care * Healthy subjects will be invited to participate to constitute the control group. If they are willing to participate a blood sample (9 ml) will be drawn specifically for this study
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-05-02; most recent amendment 2025-05-13.
Status change: Not Yet Recruiting → Recruiting 2023-07-07
Trial Details
NCT Number NCT05854368
Lead Sponsor Institut Pasteur
Collaborators: Assistance Publique - Hôpitaux de Paris
Conditions Gastric Lesion, Gastric Precancerous Condition, Gastric Cancer
Enrollment 2,500 participants
Start Date 2023-07-03
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-16